2 results
Approved WMOCompleted
To evaluate the safety and effectiveness of the OMGEA Coronary Stent System for the treatment of subjects with a de novo atherosclerotic coronary artery lesion * 28 mm in length (by visual estimate) in a native coronary artery *2.25 mm to *4.50 mm…
Approved WMORecruiting
Primary Objectives 1. To evaluate the efficacy of clazakizumab in preventing all-cause composite allograft loss (including death) due to CABMR.2. To evaluate the efficacy of clazakizumab in slowing/preventing the progressive loss of kidney function…